The role of immunohistochemistry in the differential diagnosis of breast lesions

Pathology

Volumn 41, Issue 1, 2009, Pages 68-76

  Moriya, Takuya ^a   Kozuka, Yuji ^a   Kanomata, Naoki ^a   Tse, Gary M ^b   Tan, Puay Hoon ^c  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Apocrine; Breast; Breast carcinoma; Cytokeratin; Ductal carcinoma in situ; Immunohistochemistry; Myoepithelial cell; Neuroendocrine; Papilloma; Phyllodes tumour; Spindle cell carcinoma

Indexed keywords

BIOLOGICAL MARKER; CYTOKERATIN; UVOMORULIN;

APOCRINE GLAND; BREAST CARCINOMA; BREAST LESION; BREAST PAPILLOMA; CANCER DIAGNOSIS; CELL POPULATION; CYSTOSARCOMA PHYLLOIDES; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; EPITHELIUM CELL; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; INVASIVE CARCINOMA; LUNG CARCINOMA; MYOEPITHELIUM CELL; REVIEW; SENSITIVITY AND SPECIFICITY; SPINDLE CELL CARCINOMA;

EID: 57749089559     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1080/00313020802563544     Document Type: Article

References (59)

1. MacGrogen G, Monifar F, Raju U. Intraductal papillary neoplasms. In: Tavassoli FA, Devilee P, editors. Tumours of the Breast and Female Genital Organs. Lyon: IARC Press, 2003; 76-80.
2. Mulligan A, O'Malley FP. Papillary lesions of the breast. A review. Adv Anat Pathol 2007; 14: 108-19.
3. Collins LC, Schnitt SJ. Papillry lesions of the breast. Selected diagnostic and management issues. Histopathology 2008; 52: 20-9.
4. Oyama T, Koener FC. Noninvasive papillary proliferations. Semin Diagn Pathol 2004; 21: 32-41.
5. Tamai M. Intraductal growth of malignant mammary myoepithelioma. Am J Surg Pathol 1992; 16: 1116-25.
6. Moriya T, Kasajima A, Ishida K, et al. New trends of immunohistochemistry for making differential diagnosis of breast lesions. Med Mol Morphol 2006; 39: 8-13.
7. Troxell ML, Masek M, Sibley RK. Immunohistochemical staining of papillary lesions. Appl Immunohistochem Mol Morphol 2007; 15: 145-53.
8. Collins LC, Carlo VP, Hwang H, et al. Intracystic papillary carcinomas of the breast. A reevaluation using a panel of myoepithelial cell markers. Am J Surg Pathol 2006; 30: 1002-7.
9. Ichihara S, Fijimoto T, Hashimoto K, et al. Double immunostaining with p63and high-molecular-weight cytokeratins distinguishes borderline papillary lesion of the breast. Pathol Int 2007; 57: 126-32.
10. Wang X, Mori I, Tang W, et al. p63 expression in normal, hyperplastic and malignant breast tissues. Breast Cancer 2002; 9: 216-9.
11. Bhargava R, Dabbs DJ. Use of immunohistochemistry in diagnosis of breast epithelial lesions. Adv Anat Pathol 2007; 14: 93-107.
12. Tse GM, Tan PH, Lui PC, et al. The role of immunohistochemistry for smooth muscle actin, p63, CD10 and cytokeratin 14 in the differential diagnosis of the breast. J Clin Pathol 2007; 60: 315-20.
13. Reis-Filho JS, Steele D, Di Palma S, et al. Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue. Mod Pathol 2006; 19: 307-19.
14. Hasegawa M, Hagiwara S, Sato T, et al. CD109, a new marker for myoepithelial cells of mammary, salivary, and lacrimal glands and prostate basal cells. Pathol Int 2007; 57: 245-50.
15. Tse GM, Tan PH, Chaiwun B, et al. p63 is useful in the diagnosis of mammary metaplastic carcinomas. Pathology 2006; 38: 16-20.
16. Koker MM, Kleer CG. p63 expression in breast cancer: a highly sensitive and specific marker of metaplastic carcinoma. Am J Surg Pathol 2004; 28: 1506-12.
17. Hill CB, Yeh IT. Myoepithelial cell staining patterns of papillary breast lesions. From intraductal papillomas to invasive papillary carcinomas. Am J Clin Pathol 2005; 123: 36-44.
18. Nicolas MM, Wu Y, Middleton LP, et al. Loss of myoepithelium is variable in solid papillary carcinoma of the breast. Histopathology 2007; 51: 657-65.
19. Ichihara S, Koshikawa T, Nakamura S, et al. Epithelial hyperplasia of usual type express both S100-alpha and S100-beta in a heterogeneous pattern but ductal carcinoma in situ can express only S-100-alpha in a monotonous pattern. Histopathology 1997; 30: 533-41.
20. Abdel-Fatah TMA, Powe DG, Nodi Z, et al. Morphological and molecular evolutionary pathways of low nuclear grade invasive cancers and their putative precursor lesions. Future evidence to support the concept of low nuclear grade breast neoplasia family. Am J Surg Pathol 2008; 32: 513-23.
21. Bocker W, Burger H, Buchwalow IB, et al. CK5-positive cells are precursor cells of glandular and myoepithelial cell lineages in the human breast epithelium. A new cell concept as a basis for a better understanding of proliferative breast disease? Verh Dtsch Ges Pathol 2005; 89: 45-7.
22. Korsching E, Jeffrey SS, Meinerz W, et al. Basal carcinoma of the breast revisited: an old entity with new interpretations. J Clin Pathol 2008; 61: 553-60.
23. Livasy CA, Perou CM, Karaca G, et al. Identification of a basal-like subtype of breast ductal carcinoma in situ. Hum Pathol 2007; 38: 197-204.
24. Bocker W, Burger H, Buchwalow IB, et al. Ck5-positive cells are precursor cells of glandular and myoepithelial cell lineages in the human breast epithelium. A new cell concept as a basis for better understanding of proliferative breast disease? Verh Dtsch Ges Pathol 2005; 89: 45-7.
25. Tan PH, Yuan M, Yip G, et al. Cytokeratins in papillary lesions of the breast. Is there a role in distinguishing intraductal papilloma from papillary ductal carcinoma in situ? Am J Surg Pathol 2005; 29: 625-32.
26. Tse GM, Tan PH, Ma TF, et al. CD44s useful in the differentiation of benign and malignant papillary lesions of the breast. J Clin Pathol 2005; 58: 1185-8.
27. Maluf HM, Koerner FC. Solid papillary carcinoma of the breast. A form of intraductal carcinoma with endocrine differentiation frequently associated with mucinous carcinoma. Am J Surg Pathol 1995; 19: 1237-44.
28. Nassar H, Qureshi H, Volkanadsay N, et al. Clinicopathologic analysis of solid papillary carcinoma of the breast and associated invasive carcinomas. Am J Surg Pathol 2006; 30: 501-7.
29. Kawasaki T, Nakamura S, Sakamoto G, et al. Neuroendocrine ductal carcinoma in situ (NE-DCIS) of the breast. Comparative clinicopathological study of 20 NE-DCIS cases and 274 non-NE-DCIS cases. Histopathology 2008; 53: 288-98.
30. Moritani S, Ichihara S, Kushima R, et al. Myoepithelial cells in solid variant of intraductal papillary carcinoma of the breast. A potential diagnostic pitfall and a proposal of an immunohistochemical panel in the diagnosis with intraductal papilloma with usual ductal hyperplasia. Virchows Arch 2007; 450: 539-47.
31. Otsuki Y, Yamada M, Shimizu S, et al. Solid-papillary carcinoma of the breast. Clinicopathological study of 20 cases. Pathol Int 2007; 57: 421-9.
32. Honma N, Takubo K, Arai T, et al. Comparative study of monoclonal antibody B72.3 and gross cystic disease fluid protein-15 as markers of apocrine carcinoma of the breast. APMIS 2006; 114: 712-9.
33. Moriya T, Sakamoto K, Sasano H, et al. Immunohistochemical analysis of ki-67, p53, p21, and p27 in benign and malignant apocrine lesions of the breast. Its correlation to histologic findings in 43 cases. Mod Pathol 2000; 13: 13-8.
34. Palacios J, Sarrio D, Garcia-Macias MC, et al. Frequent E-cadherin gene inactivation by loss of heterozygosity in pleomorphic lobular carcinoma of the breast. Mod Pathol 2003; 16: 674-8.
35. Tursashvili G, Bouchal J, Ehrmann J, et al. Novel immunohistochemical markers for the differentiation of lobular and ductal invasive breast carcinomas. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2007; 151: 89-64.
36. Quensi HS, Linden MD, Divine G, et al. E-cadherin status in breast cancer correlates with histologic type but does not correlate with established prognostic parameters. Am J Clin Pathol 2006; 125: 377-85.
37. Reis-Filho JS, Simpson PT, Jones C, et al. Pleomorphic lobular carcinoma of the breast. Role of comprehensive molecular pathology in characterization of an entity. J Pathol 2005; 207: 1-17.
38. Maluf HM. Differential diagnosis of solid carcinoma in situ. Semin Diagn Pathol 2004; 21: 25-31.
39. Silva LD, Parry S, Reid L, et al. Aberrant expression of E-cadherin in lobular carcinomas of the breast. Am J Surg Pathol 2008; 32: 773-83.
40. Mastracci TL, Tjan S, Bane AL, et al. E-cadherin alterations in atypical lobular hyperplasia and lobular carcinoma in situ of the breast. Mod Pathol 2005; 18: 741-51.
41. Goldstain NS, Kestin LL, Vicini FA. Clinicopathologic implications of E-cadherin reactivity in patients with lobular carcinoma in situ of the breast. Cancer 2001; 92: 738-47.
42. Wheeler DT, Tai LH, Bratthauer GL, et al. Tubulolobular carcinoma of the breast. An analysis of 27 cases of a tumor with a hybrid morphology and immunoprofile. Am J Surg Pathol 2004; 28: 1587-93.
43. Esposito NN, Chivukula M, Dabbs DJ. The ductal phenotypic expression of the E-cadherin/catenin complex in tubulolobular carcinoma of the breast. An immunohistochemical and clinicopathologic study. Mod Pathol 2007; 20: 130-8.
44. Bratthauer GL, Moinfar F, Stamatakos MD, et al. Combined E-cadherin and high molecular weight cytokeratin immunoprofile differentiates lobular, ductal, and hybrid mammary intraepithelial neoplasias. Hum Pathol 2002; 33: 620-7.
45. Lacroix-Triki M, Mery E, Voigt JJ, et al. Value of cytokeratin 5/6 immunostaining using D5/16 B4 antibody in the spectrum of proliferative intraepithelial lesions of the breast. A comparative study with 34betaE12 antibody. Virchows Arch 2003; 442: 548-54.
46. Fadare O, Wang SA, Hileeto D. The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast. Evidence of a basal-like subset? Hum Pathol 2008; 39: 331-6.
47. Lehr HA, Folpe A, Yazji H, et al. Cytokeratin 8 immunostaining pattern and E-cadherin expression distinguish lobular from ductal breast carcinoma. Am J Clin Pathol 2000; 114: 190-6.
48. Lee AH. Recent developments in the histological diagnosis of spindle cell carcinoma, fibromatosis and phyllodes tumour of the breast. Histopathology 2008; 52: 45-57.
49. Dunne B, Lee AH, Pinder SE, et al. An immunohistochemical study of metaplastic spindle cell carcinoma, phyllodes tumor and fibromatosis of the breast. Hum Pathol 2003; 34: 1009-15.
50. Abdel-Fatah TA, Powe DG, Hodi Z, et al. Morphologic and molecular evolutionary pathways of low nuclear grade invasive breast cancers and their putative precursor lesions. Further evidence to support the concept of low nuclear grade breast neoplasia family. Am J Surg Pathol 2008; 32: 513-23.
51. Tan PH, Jayabaskar T, Yip G, et al. p53 and c-kit(CD117) protein expression as prognostic indicators in breast phyllodes tumors. A tissue microarray study. Mod Pathol 2005; 18: 1537-34.
52. Esposito MN, Mohan D, Brufsky A, et al. Phyllodes tumor. A clinicopathologic and immunohistochemical study of 30 cases. Arch Pathol Lab Med 2006; 130: 1516-21.
53. Tse GM, Tan PH. Recent advances in the pathology of fibroepithelial tumours of the breast. Curr Diagn Pathol 2005; 11: 426-34.
54. Djordjevic B, Hanna WM. Expression of c-kit in fibroepithelial lesion of the breast is a mast cell phenomenon. Mod Pathol 2008; 21: 1238-45.
55. Tse GM, Putti TC, Kung FY, et al. Increased p53 protein expression in malignant mammary phyllodes tumors. Mod Pathol 2002; 15: 734-40.
56. Sawyer EJ, Hanby AM, Poulsom R, et al. Beta-catenin abnormalities and associated insulin-like growth factor overexpression are important in phyllodes tumors and fibroadenomas of the breast. J Pathol 2003; 200: 627-32.
57. De La Cruz, C, Moriya T, Endoh M, et al. Invasive micropapillary carcinoma of the breast. Clinicopathological and immunohistochemical study. Pathol Int 2004; 54: 90-6.
58. Nassar H, Pansare V, Zhang H, et al. Pathogenesis of invasive micropapillary carcinoma. Role of MUC1 glycoprotein. Mod Pathol 2004; 17: 1045-50.
59. Park SY, Kim BH, Kim JH, et al. Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma. Arch Pathol Lab Med 2007; 131: 1561-7.